Owl vs Fox answered the below Headlined article, but as much of it was copyright protected, it was moderated.
I am hoping that, by my deleting the copywrite protected compoment, Owl vs Fox's comment can still be shared.
Owl vs Fox ; "What is so encouraging is that there is so much renewed interest in the AD space with Big Pharma & therapy targets. I agree with others here, whatever way you look at it, Beta-Amyloid plaques, Tau - if you read it all, more is needed for cognition, it’s not just all about reversing these pathological processes in the brain. Combination therapy. There are also more testing capabilities for AD biomarkers being developed & commercialised. So it’s an ongoing massive development in AD.
GLTAH
The article, originally posted by @Ridge1…
AbbVie adds to its neuro pipeline with a $1B buyout deal, bolting on a new drug aimed at Alzheimer’s
Endpoints News (endpts.com)
1 March 2022
John Carroll Editor & Founder
AbbVie is beefing up its neuro pipeline with a small biotech buyout that adds a new approach to cognitive decline in Alzheimer’s and other CNS diseases.
Owl vs Fox answered the below Headlined article, but as much of...
Add ACW (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
3.1¢ |
Change
-0.001(3.13%) |
Mkt cap ! $72.13M | |||
| Open | High | Low | Value | Volume |
| 3.2¢ | 3.2¢ | 3.1¢ | $64.98K | 2.063M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 8 | 1172891 | 3.1¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 3.2¢ | 533333 | 2 |
View Market Depth
| Last trade - 16.10pm 06/05/2024 (20 minute delay) ? |
|
|||||
|
Last
3.2¢ |
Change
-0.001 ( 0.00 %) |
||||
| Open | High | Low | Volume | ||
| 3.1¢ | 3.2¢ | 3.1¢ | 1099700 | ||
| Last updated 15.16pm 06/05/2024 ? | |||||
| ACW (ASX) Chart |